I. Why Qinghai Pharmaceutical Manufacturing Merits Focused Research

In most Chinese provinces, pharmaceutical manufacturing revolves around chemical drugs and generics, following a broadly similar competitive logic. Qinghai's distinctiveness lies in the scarcity of its resource endowments: the province holds 1,660 species of traditional medicinal materials, covering 151 of the 363 priority varieties in China's national survey; its Cordyceps sinensis habitat spans 70 million mu, accounting for 60% of national output; and its organic wolfberry cultivation area ranks first in China. These three resource categories are virtually irreplicable elsewhere, giving Qinghai's pharmaceutical sector a structural focus on Tibetan medicine, Cordyceps processing, and highland plant extracts.

In 2023, Qinghai's pharmaceutical manufacturing value-added grew by 21.7% year on year, outpacing the national sector average; output of finished Chinese patent medicines reached 2,056 tonnes, up 24.6%, with four individual products each exceeding 100 million yuan in annual sales. These figures indicate that highland specialty resources are completing a transition from raw material exports toward higher-value manufacturing.

II. Geographic Clusters: Xining Development Zone as the Core

Pharmaceutical manufacturing in Qinghai is heavily concentrated in the Xining (National) Economic and Technological Development Zone Biotech Industrial Park in Chengbei District. In November 2024, this cluster was recognized as the first national-level SME specialty industrial cluster dedicated to highland bio-medicine. It hosts 118 enterprises and has the annual production capacity to process 5,000 tonnes of Tibetan and Chinese patent medicines, 80,000 tonnes of wolfberry, 50,000 tonnes of sea buckthorn, and 50,000 tonnes of chicory inulin — making it the province's largest Tibetan and Chinese medicine production base.

Yushu Tibetan Autonomous Prefecture is the primary Cordyceps production region, with the folk saying: "For China's Cordyceps, look to Qinghai; for Qinghai's Cordyceps, look to Yushu." The spatial separation between raw material origins and the manufacturing cluster makes logistics and quality control critical bottlenecks in the supply chain.

III. Leading Enterprise Landscape

Jinhe Tibetan Medicine is the core state-capital-backed enterprise in Qinghai. Its production base in the Xining Biotech Park occupies 103 mu, with capacity across 8 dosage forms and 65 NMPA-approved Tibetan drug products. The company has ranked among China's Top 100 Pharmaceutical Enterprises for five consecutive years. Its two flagship products — An'erni Granules and Ruyi Zhenbao Pills — each exceed 100 million yuan in annual sales. As of 2023, Jinhe holds 115 domestic invention patents and was recognized as a national high-tech enterprise, as well as a "2022–2023 Outstanding Brand Enterprise of Chinese Ethnic Medicine."

Jingzhu Tibetan Medicine Group is widely regarded as China's largest modern Tibetan pharmaceutical manufacturer. The group controls 18 subsidiaries spanning drug manufacturing, healthcare, research, and cultural tourism. An independent valuation assessed total group assets at 5.898 billion yuan, including brand goodwill of 3.911 billion yuan. Its 14 proprietary patented products maintain leading market share within the domestic Tibetan medicine sector.

Dadi Pharmaceuticals and other private enterprises form a secondary tier alongside these two leaders, each with annual output exceeding 100 million yuan. The 2024 entry of major outside investors — including Nanjing Guoyao — into the Xining Biotech Park signals accelerating external investment momentum.

IV. Supply Chain Structure

Upstream resources: Cordyceps sinensis, wolfberry, rhubarb, Rhodiola rosea, Swertia mussotii, and musk constitute the raw material base. Qinghai's cultivated and semi-wild medicinal plant area covers nearly 3 million mu. In 2022, Cordyceps annual output was approximately 150 tonnes, with total output value reaching 20.1 billion yuan; Cordyceps exports from Qinghai accounted for roughly 47% of China's total Cordyceps export value.

Manufacturing tier: Three main product lines: modern Tibetan patent medicines, Tibetan and Chinese herbal extracts, and highland plant functional health products. Traditional Tibetan dosage forms have been extended into granules, capsules, and tablets, improving production consistency and quality controllability.

Downstream distribution: A pharmaceutical distribution network radiates province-wide from Xining, reaching inland markets through national drug wholesalers. Cordyceps is additionally distributed nationwide through the Xining Cordyceps wholesale trading market.

R&D infrastructure: Jinhe Group is advancing construction of 13 research platforms, including the National Key Laboratory for Modern Tibetan Drug Innovation. The Xining Biotech Park has established eight shared testing and inspection platforms, providing common research infrastructure for smaller enterprises.

V. Challenges and Transformation Paths

Qinghai pharmaceutical manufacturing faces several structural constraints. First, Cordyceps resources are under pressure from over-harvesting, with significant output volatility; the tension between ecological protection and production stability cannot be resolved in the short term. Second, the threshold for obtaining NMPA approval for Tibetan drug formulas is high, and the modernization registration process for some traditional prescriptions is slow, constraining new product launch timelines. Third, local manufacturers' national sales networks remain dependent on out-of-province distributors, limiting their downstream pricing power.

Two transformation trajectories are taking shape: deepening evidence-based clinical research for existing Tibetan drug varieties to support hospital formulary inclusion; and extending wolfberry and Cordyceps processing downstream into functional foods, health supplements, and cosmetic ingredients to reduce single-channel dependence on pharmaceutical licensing.

VI. Research Institute Perspective

Qinghai's pharmaceutical competitiveness is rooted in a material foundation that only thrives above 4,000 meters in elevation — an advantage that policy cannot artificially replicate in the short term. Whether Jinhe and Jingzhu can defend their brand premium in China's modern Tibetan medicine market ultimately hinges on two factors: sustained investment in clinical evidence systems, and long-term stewardship of the raw material ecosystems in Yushu. The industry's growth ceiling is set by the carrying capacity of Yushu's grasslands, not by the pace of factory expansion.

Sales teams supplying upstream inputs to Qinghai's pharmaceutical manufacturers can use Tianxia Gongchang to filter factory directories and decision-maker contacts by province and sub-sector, enabling precise outreach to target clients.

Data Sources

  • Tianxia Gongchang (Qinghai pharmaceutical manufacturing factory directory and industry data)
  • Qinghai Provincial Government, "Highland Chinese and Tibetan Medicine Industry Innovation Report," November 2024
  • Qinghai Provincial Government, "Qinghai Pharmaceutical Manufacturing Industry Milestone," 2021
  • Qinghai Provincial Government, "Qinghai Cordyceps Annual Output Value Reaches 20.1 Billion Yuan," 2022
  • Qinghai State-owned Assets Supervision Commission, Jinhe Tibetan Medicine High-tech Enterprise Certification Announcement, October 2024
  • Qinghai Provincial Government, "Qinghai's First National-Level SME Specialty Industrial Cluster Established in Xining," November 2024
  • Qianzhan Industry Research Institute, Analysis of China's Cordyceps Export Structure, 2022